# Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers

> **NCT03060447** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 25 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Vesatolimod
- **DRUG:** Placebo
- **DRUG:** ART

## Key facts

- **NCT ID:** NCT03060447
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-09
- **Primary completion:** 2020-02-13
- **Final completion:** 2020-02-13
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03060447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03060447, "Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03060447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*